This is likely due to stabilization of the anti-apoptotic MCL-1 protein, a phenomenon previously reported in patients with CLL, DLBCL, or AML who become refractory to venetoclax [25, 29, 73]. Here, MCL1 is linked to diffuse large B-cell lymphoma.